Deoxycholic Acid clinical trials
Also written Kybella, ATX-101, DWJ211 and Deoxycholate.
Counted the way a researcher would: Deoxycholic Acid with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses Deoxycholic Acid is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Deoxycholic Acid studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 29 Apr 2015 · KYBELLA · NDA 206333 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
24 studies that test it; most in 2019 (4)
| Year | Studies |
|---|---|
| 2007 | 3 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 4 |
| 2021 | 1 |
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 16 · Other 8
Kythera Biopharmaceuticals (12) · Massachusetts General Hospital (4) · Daewoong Pharmaceutical Co. LTD. (3) · The Maas Clinic (1) · Zeltiq Aesthetics (1) · Juva Skin & Laser Center (1) · University of California, San Diego (1) · BodyAesthetic Research Center (1)
Often tested with
Tested in the same studies.
Polidocanol (2) · Lidocaine Hydrochloride/Epinephrine (1) · Loratadine (1) · Ibuprofen (1) · Phosphatidylcholines (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Deoxycholic Acid.
- Feb 2027Assessing the Efficacy of Repeat, Monthly Treatments of Deoxycholate for NF1 Associated Cutaneous Neurofibromas (cNFs)Phase 1 · Massachusetts General Hospital
Studies
Open first, then newest update. How each study uses Deoxycholic Acid is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 24
- Assessing the Efficacy of Repeat, Monthly Treatments of Deoxycholate for NF1 Associated Cutaneous Neurofibromas (cNFs)Enrolling by invitationPhase 1Massachusetts General HospitalNCT06300502Written as KybellaHow we know
- Safety and Efficacy of Deoxycholate Treatment of Small Fatty Deformities ( SFD)CompletedPhase 4The Maas ClinicNCT07880301Written as KybellaHow we know
- Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous NeurofibromasCompletedPhase 1Massachusetts General HospitalNCT06132165Written as Deoxycholic AcidHow we know
- Dosing and Tolerability of Deoxycholic Acid Vs. Polidocanol in the Treatment of Neurofibromatosis Type 1 Cutaneous NeurofibromasCompletedPhase 1Massachusetts General HospitalNCT06120036Written as KybellaHow we know
- Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous NeurofibromasCompletedPhase 1Massachusetts General HospitalNCT04730583Written as KybellaHow we know
- Evaluate the Efficacy and Safety of DWJ211 in Patient With Moderate or Severe Submental FatCompletedPhase 3Daewoong Pharmaceutical Co. LTD.NCT03946592Written as DWJ211How we know
- Clinicial Trial to Evaluate the Efficacy and Safety of DWJ211 in Patient With Moderate or Severe Submental FatCompletedPhase 2Daewoong Pharmaceutical Co. LTD.NCT03224117Written as DWJ211How we know
- Pharmacokinetics and Safety, Tolerability of DWJ211in Healthy VolunteersCompletedPhase 1Daewoong Pharmaceutical Co. LTD.NCT04159961Written as DWJ211How we know
- Submental Study (Sequential Treatment Approach)CompletedPhase 4Zeltiq AestheticsNCT03510598Written as Kybella 20 MG in 2 ML InjectionHow we know
- Efficacy and Safety of Deoxycholic Acid Injections for Removal of Adipose Tissue in the "Bra Strap Fat" RegionCompletedPhase 4Juva Skin & Laser CenterNCT04089722Written as Deoxycholic AcidHow we know
- Safety and Efficacy of Deoxycholic Acid Injection for Reduction of Upper Inner Thigh FatCompletedEarly Phase 1University of California, San DiegoNCT04054011Written as Deoxycholic AcidHow we know
- Safety Study of ATX-101 (Deoxycholic Acid) in Subjects With Mild or Extreme Fullness of Submental FatCompletedPhase 3Kythera BiopharmaceuticalsNCT02035267Written as Deoxycholic AcidHow we know
- Open-Label Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental AreaCompletedPhase 3Kythera BiopharmaceuticalsNCT01426373Written as Deoxycholic acid injectionHow we know
- Phase 2 Study for the Treatment of Superficial LipomasCompletedPhase 2Kythera BiopharmaceuticalsNCT00608842Written as Deoxycholic Acid InjectionHow we know
- Deoxycholic Acid Injection for the Treatment of Superficial LipomasCompletedPhase 1Kythera BiopharmaceuticalsNCT00422188Written as Deoxycholic Acid InjectionHow we know
- Patient Experience Study of Deoxycholic Acid InjectionCompletedPhase 3Kythera BiopharmaceuticalsNCT02007434Written as Deoxycholic Acid InjectionHow we know
- Phase 2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental FatCompletedPhase 2Kythera BiopharmaceuticalsNCT00618618Written as Deoxycholic Acid InjectionHow we know
- Phase 1-2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental FatCompletedPhase 1/2Kythera BiopharmaceuticalsNCT00618722Written as Deoxycholic Acid InjectionHow we know
- Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental FatCompletedPhase 3Kythera BiopharmaceuticalsNCT01305577Written as Deoxycholic acid injectionHow we know
- Deoxycholic Acid Injection Submental Fat (SMF) Magnetic Resonance Imaging (MRI) and Subject-reported Outcome Measures StudyCompletedPhase 2Kythera BiopharmaceuticalsNCT01032889Written as Deoxycholic acid injectionHow we know
See all 24 studies that test Deoxycholic Acid →
Given beside what is tested · 2 — Deoxycholic Acid is usual care or a partner of the new treatment
- A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica ProductsCompletedPhase 4AbbVieNCT06783621Written as KYBELLAHow we know
- Subcutaneous Sodium Deoxycholate Injections With or Without Triamcinolone for Reduction of Submental FatCompletedPhase 4Goldman, Butterwick, Fitzpatrick and GroffNCT03241563Written as Sodium DeoxycholateHow we know
As the comparator · 2 — what is tested is compared with Deoxycholic Acid
- Intralesional Ronkyla Plus Injection for the Treatment of Superficial LipomaRecruitingPhase 1Glonova Pharma Co., LtdNCT07237425Written as KybellaHow we know
- Kybella With TriamcinoloneCompletedPhase 4Goldman, Butterwick, Fitzpatrick and GroffNCT03361176Written as Injectable sodium deoxycholateHow we know
Codes
What other systems call Deoxycholic Acid · ClinicalTrials.gg INT007310
- MeSH (NLM) D003840Deoxycholic AcidConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 005990WHZZDEOXYCHOLIC ACIDConfirmed FDA, NLM, Wikidata
- RxNorm 3194Confirmed FDA, Wikidata
- Wikidata Q425680deoxycholic acidConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C81042Deoxycholic AcidConfirmed FDA, Wikidata
- DrugBank DB03619One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D003840 | Deoxycholic Acid | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 005990WHZZ | DEOXYCHOLIC ACID | Confirmed FDA, NLM, Wikidata |
| RxNorm | 3194 | — | Confirmed FDA, Wikidata |
| Wikidata | Q425680 | deoxycholic acid | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C81042 | Deoxycholic Acid | Confirmed FDA, Wikidata |
| DrugBank | DB03619 | — | One source Wikidata |
Also registered as sodium desoxycholate (UNII 436LS6U35Y).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.